Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 5,387 Shares

Key Points

• Insider sale: Elizabeth Lin sold 5,387 Tarsus Pharmaceuticals shares at $80 each for $430,960, reducing her direct ownership by 28.8%. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, alongside two other recent sales.
• Stock performance: TARS traded at $83.21, near its 52-week high of $85.25, with a market capitalization of approximately $3.65 billion. The company reported quarterly revenue of $173.91 million but missed analysts’ EPS expectations.
• Analyst outlook: Analysts maintain a consensus “Moderate Buy” rating with an average price target of $90.50, although ratings range from “Strong Buy” to “Sell.” Institutional investors own approximately 90.01% of the company’s shares.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Elizabeth Lin sold 5,387 shares of Tarsus Pharmaceuticals stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $80.00, for a total value of $430,960.00. Following the transaction, the insider directly owned 13,320 shares of the company's stock, valued at approximately $1,065,600. This represents a 28.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Wednesday, September 2nd, Elizabeth Lin sold 1,590 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $80.00, for a total transaction of $127,200.00.
• On Tuesday, September 1st, Elizabeth Lin sold 4,601 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $73.86, for a total value of $339,829.86.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock traded up $0.45 during midday trading on Thursday, reaching $83.21. 733,653 shares of the company were exchanged, compared to its average volume of 744,913. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.17 and a current ratio of 3.20. The company has a market capitalization of $3.65 billion, a price-to-earnings ratio of -76.34 and a beta of 0.54. The firm's 50-day simple moving average is $65.08 and its 200-day simple moving average is $65.59. Tarsus Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.24). The firm had revenue of $173.91 million for the quarter, compared to analyst estimates of $169.65 million. Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%. On average, analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -2.06 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on TARS shares. HC Wainwright reissued a "buy" rating and set a $88.00 target price on shares of Tarsus Pharmaceuticals in a research report on Thursday, July 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Oppenheimer raised their price objective on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 12th. Finally, Guggenheim dropped their price target on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a "buy" rating on the stock in a research report on Tuesday, July 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $90.50.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Rockefeller Capital Management L.P. boosted its stake in shares of Tarsus Pharmaceuticals by 15.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company's stock valued at $105,000 after buying an additional 172 shares during the period. Parallel Advisors LLC boosted its position in Tarsus Pharmaceuticals by 139.2% during the first quarter. Parallel Advisors LLC now owns 500 shares of the company's stock worth $35,000 after purchasing an additional 291 shares during the period. State of Wisconsin Investment Board grew its stake in Tarsus Pharmaceuticals by 1.1% in the 4th quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company's stock valued at $2,613,000 after buying an additional 332 shares during the last quarter. Federated Hermes Inc. grew its position in shares of Tarsus Pharmaceuticals by 0.6% in the second quarter. Federated Hermes Inc. now owns 55,021 shares of the company's stock valued at $2,229,000 after purchasing an additional 339 shares during the last quarter. Finally, Valeo Financial Advisors LLC grew its holdings in Tarsus Pharmaceuticals by 11.1% in the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company's stock valued at $321,000 after buying an additional 392 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source